Quality of life in transfusion-dependent thalassaemia patients on desferrioxamine treatment

Maznah Dahlui, M. I. Hishamshah, A. Rahman A. Jamal, Syed Mohamed Al-Junid Syed Junid

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Introduction: The quality of life of transfusion-dependent thalassaemia patients is affected by the disease itself and iron overload complications from repeated blood transfusion. Desferrioxamine has been used to remove the excess iron, resulting in decreased mortality and morbidity. In Malaysia, a significant proportion of the transfusion-dependent thalassaemia patients are not prescribed desferrioxamine, due to its high cost, especially as it is not subsidised by the government. The aim of this study was to measure the quality of life of thalassaemia patients on desferrioxamine treatment. Methods: A cross-sectional study was performed on all transfusion-dependent thalassaemia patients on follow-up at two tertiary hospitals in Kuala Lumpur, Malaysia, in 2005. Quality-of-life scores were measured by using the translated MOS SF-36 questionnaires, while diseases related to iron overload complications were obtained from the medical records. Use of desferrioxamine was elicited through interviews and validated by drug records. Quality-adjusted life-years (QALYs) presented were formulated from residual life-years and quality-of-life scores. Results: A total of 112 transfusion-dependent thalassaemia patients were recruited, with 54 (48 percent) and 58 (52 percent) patients on sub-optimum and optimum desferrioxamine treatments, respectively. QALYs were higher in patients on optimum desferrioxamine (9.04, standard deviation [SD] 2.46) than patients on sub-optimum desferrioxamine (5.12, SD 2.51). QALYs were associated with the level of serum ferritin, iron overload complications and total family income. Conclusion: Optimum desferrioxamine usage reduces iron overload complications and provides a better quality of life.

Original languageEnglish
Pages (from-to)794-799
Number of pages6
JournalSingapore Medical Journal
Volume50
Issue number8
Publication statusPublished - 1 Aug 2009

Fingerprint

Deferoxamine
Thalassemia
Quality of Life
Iron Overload
Quality-Adjusted Life Years
Malaysia
Therapeutics
Ferritins
Tertiary Care Centers
Blood Transfusion
Medical Records
Iron
Cross-Sectional Studies
Interviews
Morbidity
Costs and Cost Analysis
Mortality
Serum

Keywords

  • Desferrioxamine treatment
  • Iron overload complications
  • Quality of life
  • Quality-adjusted life-years
  • Transfusion-dependent thalassaemia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Quality of life in transfusion-dependent thalassaemia patients on desferrioxamine treatment. / Dahlui, Maznah; Hishamshah, M. I.; A. Jamal, A. Rahman; Syed Junid, Syed Mohamed Al-Junid.

In: Singapore Medical Journal, Vol. 50, No. 8, 01.08.2009, p. 794-799.

Research output: Contribution to journalArticle

@article{41a63ada25534bad9442e89245c92459,
title = "Quality of life in transfusion-dependent thalassaemia patients on desferrioxamine treatment",
abstract = "Introduction: The quality of life of transfusion-dependent thalassaemia patients is affected by the disease itself and iron overload complications from repeated blood transfusion. Desferrioxamine has been used to remove the excess iron, resulting in decreased mortality and morbidity. In Malaysia, a significant proportion of the transfusion-dependent thalassaemia patients are not prescribed desferrioxamine, due to its high cost, especially as it is not subsidised by the government. The aim of this study was to measure the quality of life of thalassaemia patients on desferrioxamine treatment. Methods: A cross-sectional study was performed on all transfusion-dependent thalassaemia patients on follow-up at two tertiary hospitals in Kuala Lumpur, Malaysia, in 2005. Quality-of-life scores were measured by using the translated MOS SF-36 questionnaires, while diseases related to iron overload complications were obtained from the medical records. Use of desferrioxamine was elicited through interviews and validated by drug records. Quality-adjusted life-years (QALYs) presented were formulated from residual life-years and quality-of-life scores. Results: A total of 112 transfusion-dependent thalassaemia patients were recruited, with 54 (48 percent) and 58 (52 percent) patients on sub-optimum and optimum desferrioxamine treatments, respectively. QALYs were higher in patients on optimum desferrioxamine (9.04, standard deviation [SD] 2.46) than patients on sub-optimum desferrioxamine (5.12, SD 2.51). QALYs were associated with the level of serum ferritin, iron overload complications and total family income. Conclusion: Optimum desferrioxamine usage reduces iron overload complications and provides a better quality of life.",
keywords = "Desferrioxamine treatment, Iron overload complications, Quality of life, Quality-adjusted life-years, Transfusion-dependent thalassaemia",
author = "Maznah Dahlui and Hishamshah, {M. I.} and {A. Jamal}, {A. Rahman} and {Syed Junid}, {Syed Mohamed Al-Junid}",
year = "2009",
month = "8",
day = "1",
language = "English",
volume = "50",
pages = "794--799",
journal = "Singapore Medical Journal",
issn = "0037-5675",
publisher = "Singapore Medical Association",
number = "8",

}

TY - JOUR

T1 - Quality of life in transfusion-dependent thalassaemia patients on desferrioxamine treatment

AU - Dahlui, Maznah

AU - Hishamshah, M. I.

AU - A. Jamal, A. Rahman

AU - Syed Junid, Syed Mohamed Al-Junid

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Introduction: The quality of life of transfusion-dependent thalassaemia patients is affected by the disease itself and iron overload complications from repeated blood transfusion. Desferrioxamine has been used to remove the excess iron, resulting in decreased mortality and morbidity. In Malaysia, a significant proportion of the transfusion-dependent thalassaemia patients are not prescribed desferrioxamine, due to its high cost, especially as it is not subsidised by the government. The aim of this study was to measure the quality of life of thalassaemia patients on desferrioxamine treatment. Methods: A cross-sectional study was performed on all transfusion-dependent thalassaemia patients on follow-up at two tertiary hospitals in Kuala Lumpur, Malaysia, in 2005. Quality-of-life scores were measured by using the translated MOS SF-36 questionnaires, while diseases related to iron overload complications were obtained from the medical records. Use of desferrioxamine was elicited through interviews and validated by drug records. Quality-adjusted life-years (QALYs) presented were formulated from residual life-years and quality-of-life scores. Results: A total of 112 transfusion-dependent thalassaemia patients were recruited, with 54 (48 percent) and 58 (52 percent) patients on sub-optimum and optimum desferrioxamine treatments, respectively. QALYs were higher in patients on optimum desferrioxamine (9.04, standard deviation [SD] 2.46) than patients on sub-optimum desferrioxamine (5.12, SD 2.51). QALYs were associated with the level of serum ferritin, iron overload complications and total family income. Conclusion: Optimum desferrioxamine usage reduces iron overload complications and provides a better quality of life.

AB - Introduction: The quality of life of transfusion-dependent thalassaemia patients is affected by the disease itself and iron overload complications from repeated blood transfusion. Desferrioxamine has been used to remove the excess iron, resulting in decreased mortality and morbidity. In Malaysia, a significant proportion of the transfusion-dependent thalassaemia patients are not prescribed desferrioxamine, due to its high cost, especially as it is not subsidised by the government. The aim of this study was to measure the quality of life of thalassaemia patients on desferrioxamine treatment. Methods: A cross-sectional study was performed on all transfusion-dependent thalassaemia patients on follow-up at two tertiary hospitals in Kuala Lumpur, Malaysia, in 2005. Quality-of-life scores were measured by using the translated MOS SF-36 questionnaires, while diseases related to iron overload complications were obtained from the medical records. Use of desferrioxamine was elicited through interviews and validated by drug records. Quality-adjusted life-years (QALYs) presented were formulated from residual life-years and quality-of-life scores. Results: A total of 112 transfusion-dependent thalassaemia patients were recruited, with 54 (48 percent) and 58 (52 percent) patients on sub-optimum and optimum desferrioxamine treatments, respectively. QALYs were higher in patients on optimum desferrioxamine (9.04, standard deviation [SD] 2.46) than patients on sub-optimum desferrioxamine (5.12, SD 2.51). QALYs were associated with the level of serum ferritin, iron overload complications and total family income. Conclusion: Optimum desferrioxamine usage reduces iron overload complications and provides a better quality of life.

KW - Desferrioxamine treatment

KW - Iron overload complications

KW - Quality of life

KW - Quality-adjusted life-years

KW - Transfusion-dependent thalassaemia

UR - http://www.scopus.com/inward/record.url?scp=70349302143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349302143&partnerID=8YFLogxK

M3 - Article

VL - 50

SP - 794

EP - 799

JO - Singapore Medical Journal

JF - Singapore Medical Journal

SN - 0037-5675

IS - 8

ER -